摘要
探讨盐酸替罗非班联合硝普钠、硝酸甘油或维拉帕米经冠脉给药治疗急性ST段抬高型心肌梗死(STEMI)PCI术中无复流(NR)的疗效。选择急诊PCI术中出现NR的患者68例,随机分为盐酸替罗非班分别联合硝普钠组、硝酸甘油组及维拉帕米组,复查冠脉造影,观察冠脉TIMI血流状况、校正血流TIMI帧数以及术后不良事件的发生率。盐酸替罗非班联合硝普钠组冠脉TIMI血流达3级约82.6%,盐酸替罗非班联合维拉帕米组约78.3%,两组均高于盐酸替罗非班联合硝酸甘油组约31.8%(P<0.05),三组在住院期间均未发生死亡,各组不良反应的发生率两两之间差异无统计学意义(P>0.05)。盐酸替罗非班联合硝普钠或维拉帕米相较于盐酸替罗非班联合硝酸甘油对PCI术NR的疗效更显著。
To investigate the curative effect of Tirofiban Hydrochloride combined with Sodium Nitroprusside or Nitroglycerin or Verapamil by coronary artery for treatment of acute ST segment myocardial infarction（ STEMI） in no reflow（ NR） after emergency percutaneous coronary intervention（ PCI）. 68 patients of Emergency PCI in intraoperative with NR patients 68 cases were divided into Tirofiban Hydrochloride with Sodium Nitroprusside,Tirofiban Hydrochloride with Nitroglycerin and Tirofiban Hydrochloride with Verapamil randomly,to observe coronary artery TIMI flow conditions,corrected TIMI frame count,and blood flow to the incidence of postoperative adverse events. The group of Tirofiban Hydrochloride combined with Sodium Nitroprusside had coronary artery TIMI flow grade 3 about 82. 6%,The group of Tirofiban Hydrochloride combined with Verapamil about 78. 3%,two group were higher than that of Tirofiban Hydrochloride combined with Nitroglycerin about 31. 8%（ P〈0. 05）,No death occurred in all three groups during hospitalization,and the incidence of adverse reactions in each group was not statistically significant（ P〉0.05）. Tirofiban Hydrochloride combined with Sodium Nitroprusside or Verapamil is more effective than Tirofiban Hydrochloride combined with Nitroglycerin for the treatment of no reflow after emergency PCI.
作者
秦忠心
宋波
高波
王冰
朱含秋
张茜
肖小鸿
操传斌
QIN Zhong-xin;SONG Bo;GAO Bo(Department of Cardiology,Suizhou Affiliated Hospital of Hubei University of Medicine,Suizhou 441300, China)
出处
《医学与哲学（B）》
2018年第4期30-32,共3页
Medicine & Philosophy(B)
基金
2017年湖北省教育厅科学研究计划指导性项目(B2017482)
2016年湖北省随州市卫计委医学科研项目(2016SZ32010)
关键词
急性心肌梗死
无复流
盐酸替罗非班
acute myocardial infarction
no reflow
Tirofiban Hydrochloride
作者简介
秦忠心（1979-）,男,硕士,副主任医师,研究方向：冠心病及高血压的发病机制及治疗.;通讯作者：操传斌（1963-）,男,硕士,主任医师,教授,研究方向：冠心病及高血压的诊断及治疗.E-mail：ccbhbsz@163.com
